Analysis of fruquintinib in patients with metastatic colorectal cancer who were enrolled in Spain: results from the global FRESCO-2 study
Results were consistent with the global FRESCO-2 study population, therefore supporting fruquintinib as a new treatment option for patients with refractory mCRC.
Authors
- R. Garcia-Carbonero
- Arvind N. Dasari (ORCID: https://orcid.org/0000-0001-5271-9744)
- J. Tabernero
- E. Elez
- Zhihua Yang (ORCID: https://orcid.org/0000-0002-9301-0317)
- Paula Jiménez‐Fonseca (ORCID: https://orcid.org/0000-0003-4592-3813)
- Hong Zhu (ORCID: https://orcid.org/0000-0002-9024-0221)
- William R. Schelman
- A. Cubillo Gracían
- M. Limón Miron
- S. Lonardi
- Pilar García‐Alfonso (ORCID: https://orcid.org/0000-0002-4373-9978)
- Li‐Fen Chen (ORCID: https://orcid.org/0000-0002-3819-853X)
- Rafael Lopez (ORCID: https://orcid.org/0000-0002-1088-3594)
Institutions
- Hebron University (PS)
- Fauna and Flora International (GB)
- The University of Texas MD Anderson Cancer Center (US)
- Hospital General Universitario Gregorio Marañón (ES)
- Research Institute Hospital 12 de Octubre (ES)
- Hospital Universitario 12 De Octubre (ES)
- Vall d'Hebron Institut de Recerca (ES)
- Istituto Oncologico Veneto (IT)
- Vall d'Hebron Hospital Universitari (ES)
- Hospital Universitario Central de Asturias (ES)
- Hospital Universitario HM Sanchinarro (ES)
- Takeda (United States) (US)
- Instituto de Investigación Sanitaria de Santiago (ES)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Hospital Universitario Virgen del Rocío (ES)
Publication Details
- Journal
- ESMO Gastrointestinal Oncology
- Published
- 2025-07-16
- DOI
- https://doi.org/10.1016/j.esmogo.2025.100205
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Takeda Pharmaceuticals U.S.A.